On 21 June 2004, orphan designation (EU/3/04/206) was granted by the European Commission to Immuno-Designed Molecules, SA, France, for muramyl tripeptide phosphatidyl ethanolamine for the treatment of osteosarcoma. Immuno-Designed Molecules, SA changed its name to IDM Pharma, SA in January 2009.
The sponsorship was transferred to Takeda France SAS, France, in August 2013.
Muramyl tripeptide phosphatidyl ethanolamine in has been authorised in the EU as Mepact since 6 March 2009.
Muramyl tripeptide phosphatidyl ethanolamine
|Disease / condition||
Treatment of osteosarcoma
|Date of first decision||
|EU designation number||
Sponsor's contact details
11-13 cours Valmy
Tel. +33 1 46 25 12 51
Fax +33 1 46 97 00 11
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;